Paraformaldehyde-induced keratitis after photorefractive keratectomy.

Am J Ophthalmol

Department of Ophthalmology, School of Health Sciences, University of Crete, Greece.

Published: September 1992

We examined three patients who developed keratitis after myopic photorefractive keratectomy. All patients were treated on the same day and in all three cases paraformaldehyde tablets were used for disinfection of the excimer laser iris cone. All patients developed an intense postoperative corneal inflammation that resulted in corneal opacities. In the first patient, the opacities were central and persisted for at least 4 1/2 months postoperatively. He became more myopic than before the operation. His best spectacle-corrected visual acuity worsened by four Snellen lines. In the other two patients, the corneal opacities were paracentral and of less density. Six months postoperatively, these opacities were barely seen. In these two patients the postoperative best spectacle-corrected visual acuity remained unchanged or improved one Snellen line compared to the preoperative level. In all three patients, astigmatism increased postoperatively. These observations suggest that paraformaldehyde tablets are not safe for the disinfection of the excimer laser iris cone.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0002-9394(14)71802-1DOI Listing

Publication Analysis

Top Keywords

photorefractive keratectomy
8
three patients
8
patients developed
8
paraformaldehyde tablets
8
disinfection excimer
8
excimer laser
8
laser iris
8
iris cone
8
corneal opacities
8
months postoperatively
8

Similar Publications

The study aimed to compare the effects of different types of excimer laser keratectomy on rabbit corneas and to identify the optimal disease model for corneal ectasia. Additionally, investigating the structural and molecular alterations in the novel disease model helped explore the mechanisms underlying biomechanical cues in corneal ectasia. 2.

View Article and Find Full Text PDF

(1) Background: The phenotypes of classic lattice corneal dystrophy (LCD) and granular corneal dystrophy type 2 (GCD2) that result from abnormalities in gene () have previously been described. The phenotype of compound heterozygous classic LCD and GCD2, however, has not yet been reported. (2) Case report: A 39-year-old male (proband) presented to our clinic complaining of decreased vision bilaterally.

View Article and Find Full Text PDF

Purpose: To describe a three-phase surgical approach for managing progressive visual decline in a patient with myopia magna and a history of epikeratophakia.

Methods: A 55-year-old woman with previous epikeratophakia surgery in both eyes experienced progressive visual deterioration. The three-phase approach included: (1) removal of the epikeratophakia lenticule, (2) cataract extraction with intraocular lens implantation, and (3) transepithelial topography-guided photorefractive keratectomy (trans-PRK).

View Article and Find Full Text PDF

We present the case of a 23-year-old male who experienced vision loss in his left eye 15 months after undergoing bilateral transepithelial photorefractive keratectomy (T-PRK). Despite the absence of any significant preoperative topographical risk factors in either eye, corneal ectasia was later confirmed in the left eye, while the right eye remained normal. Subtle asymmetry in topometric indices and a borderline high Index of vertical asymmetry (IVA) reading suggested the possibility of early subclinical keratoconus, potentially increasing the risk of post-refractive ectasia.

View Article and Find Full Text PDF

Several studies in rabbits demonstrated the efficacy and safety of topical losartan, an angiotensin II receptor blockers (ARB) that modulates the TGF-β intracellular signaling pathways by inhibiting the activation of Extracellular Signal-regulated Kinase (ERK), in preventing or treating stromal fibrosis after a range of injuries such as Descemetorhexis, alkali burns, incisions, and photorefractive keratectomy (PRK). Several case reports have shown that topical losartan treatment is also efficacious and safe in humans to prevent or treat stromal fibrosis after many different injuries or diseases. Topical losartan penetrates the full thickness of the cornea and, therefore, can treat both anterior and posterior stromal fibrosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!